Streetbeat News

Regulatory

DWAC

FRTX

RDHL

Digital World (DWAC) has reached a settlement with the SEC, which will allow for a review of its Form S-4 Registration Statement. Fresh Tracks (FRTX) has announced an $8.25 million buyout of its right to receive future Sofpironium Bromide payments from Botanix. RedHill (RDHL) has announced additional U.S. government funding for Opaganib Nuclear Countermeasure Development.

Portfolio Pulse from ryanfaloona@benzinga.com

July 21, 2023 | 12:31 pm

SGBX

Safe & Green Holdings (SGBX) has regained compliance with Nasdaq's continued listing requirements, thereby avoiding potential delisting.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:31 pm

DWAC

Digital World Acquisition Corp (DWAC) has reached a settlement with the SEC, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:18 pm

JAZZ

The European Medicines Agency's CHMP has recommended the approval of Jazz Pharmaceuticals' JZP458 for use as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia, lymphoblastic lymphoma.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:12 pm

GENE

Genetic Technologies has received a notification from Nasdaq regarding a minimum bid price deficiency. The company's stock, GENE, has been trading below the minimum $1.00 per share requirement for continued listing.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:07 pm

CHEA

Trading of Chenghe Acquisition Corp. (CHEA) shares has been halted due to pending news.

Portfolio Pulse from Charles Gross

July 21, 2023 | 12:04 pm

BTCY

Biotricity has regained compliance with Nasdaq listing requirements.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:03 pm

NVCR

Novocure has received a positive recommendation from an independent data monitoring committee to continue its Phase 3 PANOVA-3 trial. The trial is evaluating the effectiveness of Tumor Treating Fields Therapy in treating pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:02 pm

BGNE

BeiGene (NASDAQ:BGNE) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval for tislelizumab as a treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Portfolio Pulse from Charles Gross

July 21, 2023 | 11:58 am

MRK

Merck (NYSE:MRK) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for gefapixant, a non-narcotic oral selective P2X3 receptor antagonist developed for the treatment of adults with chronic cough. The recommendation will be reviewed by the European Commission for marketing authorization in the EU, with a final decision expected later this year.

Portfolio Pulse from Charles Gross

July 21, 2023 | 11:53 am